- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03539718
Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.
Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters.
Study Overview
Status
Intervention / Treatment
Detailed Description
In this study,investigators will recruit 60 patients with ESRD on regular hemodialysis from hemodialysis units in Ain-Shams university Hospitals, Patients will be recruited to study at the time of catheter insertion.
They will be randomized into 2 groups. Group 1; 30 Patients will receive unfractionated heparin (5000i.u/ml) after hemodialysis sessions (control group).
Group 2; 30 Patients will receive Taurolock-hep500™ after hemodialysis sessions. All patients will be subjected to;
- Full history including history of ESRD and dialysis initiation.
- Clinical examination. Aseptic technique will be used in handling with catheters including (sterile gloves, antiseptic solution in dealing with covers and caps topical antibiotics spray and ointment) catheter will be instilled by 10 ml of normal saline in both opening followed by either taurolock hep 500™ or unfractionated heparin 5000 iu/ml.
Patients will be followed up for one month and will be monitored for clinical symptoms and signs of catheter related bacteremia (fever ,rigors, hypotension, sweating ) on the hemodialysis sessions . Also catheter performance will be assessed using the following parameters;
- Blood flow rate measured by hemodialysis machine blood pump in (ml/min).
- Dialysis quality by URR( urea reduction ratio) is a dimensionless number used to quantify dialysis treatment adequacy by calculating difference between urea level before and after hemodialysis session (average of 4 sessions , 1 per each week).
- CBC ,markers of inflammation (CRP) baseline and at time of appearance of symptoms and signs of bacteremia in both groups in addition to (IL6) measured by Elisa technique baseline and at time of appearance of symptoms and signs .
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Magdy Sharkawy, MD
- Phone Number: 002010-014-22331
- Email: Magdi35@hotmail.com
Study Contact Backup
- Name: Amr Mansour, Msc
- Phone Number: 00201007212824
- Email: Theamr19@gmail.com
Study Locations
-
-
-
Cairo, Egypt, 002
- Recruiting
- Ain Shams University Hospitals
-
Principal Investigator:
- magdy Mohamed Saeed El Sharkawy, MD
-
Contact:
- amr m mansour, Msc
- Phone Number: 1007212824
- Email: theamr19@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients on regular hemodialysis 3sessions/wk.
- Recent catheter insertion at beginning of the study.
- Both males and females.
- Age group ≥ 18 ys.
Exclusion Criteria:
- Patients with intercurrent infections.
- Patients with sepsis.
- Patients receiving drugs affecting immune system like immunosuppressive drugs.
- Patients on antibiotics.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cases
Cases, taurolidine heparin 500 will be used at end of session
|
Taurolock-hep 500 at end of session
Other Names:
|
Active Comparator: control
Controls, Heparin Sodium 5000 will be given at end of session
|
Heparin sodium 5000 at end of session
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevention of inflammation in hemodialysis patients through hemodialysis catheters
Time Frame: one month
|
Comparing levels of highly sensitive c-reactive protein and interleukin-6 levels before and after using the drug Urea reduction ratio over sessions
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Magdy Sharkawy, MD, Ain Shams University
Publications and helpful links
General Publications
- FOGARTY, DAMIAN, and PETER MAXWELL.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- taurolock hep 500 efficacy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis Catheter Infection
-
Future University in EgyptCompletedHemodialysis Complication | Hemodialysis Catheter InfectionEgypt
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedHemodialysis Catheter InfectionBrazil
-
Hospital Universitario Marqués de ValdecillaCompletedHemodialysis Catheter InfectionSpain
-
AZ Sint-Jan AVCompletedCatheter Related Bloodstream Infection | Chronic Hemodialysis | Mechanical Catheter DysfunctionBelgium
-
King Abdullah International Medical Research CenterUnknownCatheter Thrombosis | Hemodialysis Catheter Infection
-
University Hospital, Clermont-FerrandMinistry of Health, France; University Hospital, Toulouse; Hôpital Edouard Herriot and other collaboratorsRecruitingTunnelled Hemodialysis Catheter InfectionFrance
-
University Hospital, ToursRecruitingInfection, Bacterial | Hemodialysis Catheter InfectionFrance
-
Hospital General "Dr. Miguel Silva" de MoreliaUniversidad Nacional Autonoma de Mexico; NAUSLIFE HEMODIALYSIS CLINICSUnknownEnd Stage Renal Disease | Hemodialysis Access Failure | Vascular Access Complication | Catheter Complications | Hemodialysis Catheter InfectionMexico
-
C. R. BardTerminatedEnd Stage Renal Disease | Kidney Failure, Chronic | Hemodialysis Access Failure | Hemodialysis Complication | Central Venous Catheter Related Bloodstream Infection | Hemodialysis Catheter InfectionUnited States
-
Coney Island Hospital, Brooklyn, NYCompletedEnd Stage Renal Disease | Hemodialysis Access Failure | Hemodialysis Complication | Acute Renal Failure | Hemodialysis Catheter Infection | Hemodialysis Catheter-Associated Bacteremia
Clinical Trials on Taurolidine heparin
-
Universitair Ziekenhuis BrusselCompletedInfection | PatencyBelgium
-
Imperial College Healthcare NHS TrustCompletedCatheter-Related Infections | Renal DialysisUnited Kingdom
-
CorMedixPPD; Davita Clinical Research; JMI Laboratories; Spectra Clinical Research; Frenova...CompletedKidney Failure, Chronic | Catheter-Related InfectionsUnited States
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRecruitingCentral Line-associated Bloodstream Infection (CLABSI)Netherlands
-
Western Galilee Hospital-NahariyaCompletedHemodialysis | End Stage Renal DiseaseIsrael
-
Palle Bekker JeppesenTauroPharmUnknownCatheter-related Bloodstream Infection (CRBSI) NosDenmark
-
Hospital de Clinicas de Porto AlegreUnknownCatheter-Related Infections
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Stanley Dudrick's Memorial HospitalCompletedCentral Venous Catheter | Home Parenteral NutritionPoland
-
Geert WantenGeistlich Pharma AGCompletedCatheter Related Blood Stream InfectionsUnited Kingdom, Israel, Denmark, Germany, Italy, Netherlands